论中医药治疗冠心病支架植入术后再狭窄的研究进展
|
摘要
近年我国冠心病的发病率呈上升的趋势,并且死亡率远高于其他疾病。目前冠心病的治疗主要包括药物治疗、经皮冠状动脉介入治疗、冠脉旁路移植治疗等治疗手段。经皮冠状动脉介入术因其创伤较小、血管即时开通率高、并发症相对较少等优点,现在临床上被广泛运用。但与此同时再狭窄、再发心绞痛、甚至再次PCI等术后出现的事件严重影响患者的远期预后。而针对PCI术后的治疗以及并发症的防范,中医药具有依从性好、不良反应少、疗效良好等显著优势。故对中医药在冠心病PCI术后的应用进行论述。
In recent years, the incidence of coronary heart disease in China is increasing, and mortality of the disease is much higher than other diseases. At present, the coronary heart disease was mainly treated with medical treatment, percutaneous coronary intervention, coronary artery bypass grafting and other treatment methods. Percutaneous coronary intervention is widely applied in clinic because of small trauma, high blood vessel opening rate and relatively few complications. But after the operation, restenosis, angina pectoris and PCI seriously affect the long-term prognosis of patients. TCM medicine shows good compliance, fewer adverse reactions and good curative effects on PCI and complication after coronary heart disease. Therefore, the application of treating complication of coronary heart disease after PCI with TCM medicine is discussed.
In recent years, the incidence of coronary heart disease in China is increasing, and mortality of the disease is much higher than other diseases. At present, the coronary heart disease was mainly treated with medical treatment, percutaneous coronary intervention, coronary artery bypass grafting and other treatment methods. Percutaneous coronary intervention is widely applied in clinic because of small trauma, high blood vessel opening rate and relatively few complications. But after the operation, restenosis, angina pectoris and PCI seriously affect the long-term prognosis of patients. TCM medicine shows good compliance, fewer adverse reactions and good curative effects on PCI and complication after coronary heart disease. Therefore, the application of treating complication of coronary heart disease after PCI with TCM medicine is discussed.
引文
[1]Sorin J Brener,Konstanze Ertelt,Roxana Mehran,et al.Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction:Lessons from HORIZONSAMI[J].American Heart Journal,2015,169(2):242-248.
[2]刘静,安尼瓦尔·阿不里孜,黄定.629例冠心病患者经PCI术血运重建后12个月随访分析[J].新疆医科大学学报,2014,37(10):1315-1317.
[3]吕洋,王祖禄.冠心病患者中医证型与冠脉血管病变程度相关性研究[J].辽宁中医药大学学报,2017,19(10):199-202.
[4]邓鹏,胡丹,李林,等.刘中勇从浊论治经皮冠状动脉介入术后再狭窄[J].中国中医药信息杂志,2017,24(9):99-102.
[5]侯炽均,叶小汉.从积证理论探讨经皮冠脉介入术后再狭窄临床证治[J].深圳中西医结合杂志,2016,26(9):46-47.
[6]陈爱萍.中医药防治冠状动脉支架植入术后再狭窄分析[J].实用心脑肺血管病杂志,2012,20(6):1081.
[7]郭小乐,谢秋利,宋亚茹,等.李庆海教授治疗冠脉支架术后再狭窄的临证经验[J].光明中医,2016,31(4):489-491.
[8]邹国辉,李菲,曹浪,等.基于“毒瘀互结”防治冠心病支架内再狭窄的思考[J].时珍国医国药,2014,25(12):2993-2994.
[9]钱露莎,刘桂宾,李健.支架内再狭窄的危险因素及防治策略[J].医学综述,2017,23(23):4665-4670.
[10]李长江,白雪,杨思进.经皮冠状动脉介入术后支架内再狭窄的危险因素研究进展[J].现代医药卫生,2017,33(12):1798-1800.
[11]李鹤飞,陈名超,白志超,等.冠脉支架术后再狭窄危险因素分析[J].三峡大学学报(自然科学版),2017,39(S1):41-43.
[12]白中乐,邢军辉,陶海龙,等.冠状动脉内支架植入术后再狭窄的危险因素分析[J].航空航天医学杂志,2017,28(3):317-318.
[13]朱超,钱庚,任艺虹.冠状动脉介入治疗后支架内再狭窄相关因素分析[J].人民军医,2016,59(11):1147-1149.
[14]张月婷.影响冠心病PCI术后患者支架内再狭窄的因素分析[J].中外医学研究,2016,14(18):35-37.
[15]王冬梅,黄爽,刘志江,等.冠状动脉支架植入术后再狭窄危险因素的分析[J].第三军医大学学报,2016,38(19):2174-2177.
[16]姚远,梁峰,沈珠军.冠心病冠脉支架术后患者发生再狭窄的危险因素分析[J].临床和实验医学杂志,2015,14(14):1177-1179.
[17]丁立民,王大伟,李耕慧,等.冠心病患者经PCI治疗后支架内再狭窄的原因[J].世界最新医学信息文摘,2017,17(64):114.
[18]王芳,李蓓,刘成伟,等.血清mi R-663、mi R-126和mi R-370对冠心病患者支架内再狭窄的预测价值[J/OL].中国动脉硬化杂志,2017(11):1138-1142.
[19]张成彬,庆笑春,张明明,等.血红素加氧酶-1基因启动子区多态性与冠心病和冠状动脉支架内再狭窄相关性的Meta分析[J].临床心血管病杂志,2017,33(8):757-764.
[20]杨天贵,付鹏,牛铁生.血清肌酐、胱抑素C及肾小球滤过率与支架内再狭窄的相关性[J].中国动脉硬化杂志,2017,2(8):818-822.
[21]龚福汉,刘浙波,夏豪.经皮冠状动脉介入术后支架内再狭窄的相关危险因素分析[J].中华实用诊断与治疗杂志,2017,31(5):461-463.
[22]齐锋,宋柏奇.化瘀通脉颗粒干预经皮腔内冠状动脉介入治疗术后再狭窄的临床研究[J].中国中医急症,2015,24(1):44-46.
[23]代国方,王菲,黄璐.通脉口服液治疗冠心病PCI术后再狭窄的疗效观察[J/CD].中西医结合心血管病电子杂志,2015,3(17):9-10.
[24]代国方,杜廷海.益气活血中药膏方对冠脉支架植入术后气虚血瘀证患者支架内再狭窄的影响[J].中医学报,2017,32(9):1733-1736.
[25]周渭,赵小兵,周梅,等.龙脂配方颗粒防治PCI术后冠脉再狭窄的影响[J].天津中医药大学学报,2015,34(5):265-269.
[26]张建红,付玲,万贵来,等.龙脂配方颗粒对肾亏痰阻、气滞血瘀型冠心病PCI术后再狭窄的影响[J/CD].中西医结合心血管病电子杂志,2015,3(24):76-77,79.
[27]王凯丽,喻正科.护心康片干预冠心病PCI术后再狭窄32例临床观察[J].湖南中医杂志,2016,32(12):7-9.
[28]曾紫微,许滔,周竹花,等.丹蛭冰麝复方中药单体胶囊干预PCI术后再狭窄疗效研究[J].中西医结合心血管病电子杂志,2016,4(34):90-93.
[2]刘静,安尼瓦尔·阿不里孜,黄定.629例冠心病患者经PCI术血运重建后12个月随访分析[J].新疆医科大学学报,2014,37(10):1315-1317.
[3]吕洋,王祖禄.冠心病患者中医证型与冠脉血管病变程度相关性研究[J].辽宁中医药大学学报,2017,19(10):199-202.
[4]邓鹏,胡丹,李林,等.刘中勇从浊论治经皮冠状动脉介入术后再狭窄[J].中国中医药信息杂志,2017,24(9):99-102.
[5]侯炽均,叶小汉.从积证理论探讨经皮冠脉介入术后再狭窄临床证治[J].深圳中西医结合杂志,2016,26(9):46-47.
[6]陈爱萍.中医药防治冠状动脉支架植入术后再狭窄分析[J].实用心脑肺血管病杂志,2012,20(6):1081.
[7]郭小乐,谢秋利,宋亚茹,等.李庆海教授治疗冠脉支架术后再狭窄的临证经验[J].光明中医,2016,31(4):489-491.
[8]邹国辉,李菲,曹浪,等.基于“毒瘀互结”防治冠心病支架内再狭窄的思考[J].时珍国医国药,2014,25(12):2993-2994.
[9]钱露莎,刘桂宾,李健.支架内再狭窄的危险因素及防治策略[J].医学综述,2017,23(23):4665-4670.
[10]李长江,白雪,杨思进.经皮冠状动脉介入术后支架内再狭窄的危险因素研究进展[J].现代医药卫生,2017,33(12):1798-1800.
[11]李鹤飞,陈名超,白志超,等.冠脉支架术后再狭窄危险因素分析[J].三峡大学学报(自然科学版),2017,39(S1):41-43.
[12]白中乐,邢军辉,陶海龙,等.冠状动脉内支架植入术后再狭窄的危险因素分析[J].航空航天医学杂志,2017,28(3):317-318.
[13]朱超,钱庚,任艺虹.冠状动脉介入治疗后支架内再狭窄相关因素分析[J].人民军医,2016,59(11):1147-1149.
[14]张月婷.影响冠心病PCI术后患者支架内再狭窄的因素分析[J].中外医学研究,2016,14(18):35-37.
[15]王冬梅,黄爽,刘志江,等.冠状动脉支架植入术后再狭窄危险因素的分析[J].第三军医大学学报,2016,38(19):2174-2177.
[16]姚远,梁峰,沈珠军.冠心病冠脉支架术后患者发生再狭窄的危险因素分析[J].临床和实验医学杂志,2015,14(14):1177-1179.
[17]丁立民,王大伟,李耕慧,等.冠心病患者经PCI治疗后支架内再狭窄的原因[J].世界最新医学信息文摘,2017,17(64):114.
[18]王芳,李蓓,刘成伟,等.血清mi R-663、mi R-126和mi R-370对冠心病患者支架内再狭窄的预测价值[J/OL].中国动脉硬化杂志,2017(11):1138-1142.
[19]张成彬,庆笑春,张明明,等.血红素加氧酶-1基因启动子区多态性与冠心病和冠状动脉支架内再狭窄相关性的Meta分析[J].临床心血管病杂志,2017,33(8):757-764.
[20]杨天贵,付鹏,牛铁生.血清肌酐、胱抑素C及肾小球滤过率与支架内再狭窄的相关性[J].中国动脉硬化杂志,2017,2(8):818-822.
[21]龚福汉,刘浙波,夏豪.经皮冠状动脉介入术后支架内再狭窄的相关危险因素分析[J].中华实用诊断与治疗杂志,2017,31(5):461-463.
[22]齐锋,宋柏奇.化瘀通脉颗粒干预经皮腔内冠状动脉介入治疗术后再狭窄的临床研究[J].中国中医急症,2015,24(1):44-46.
[23]代国方,王菲,黄璐.通脉口服液治疗冠心病PCI术后再狭窄的疗效观察[J/CD].中西医结合心血管病电子杂志,2015,3(17):9-10.
[24]代国方,杜廷海.益气活血中药膏方对冠脉支架植入术后气虚血瘀证患者支架内再狭窄的影响[J].中医学报,2017,32(9):1733-1736.
[25]周渭,赵小兵,周梅,等.龙脂配方颗粒防治PCI术后冠脉再狭窄的影响[J].天津中医药大学学报,2015,34(5):265-269.
[26]张建红,付玲,万贵来,等.龙脂配方颗粒对肾亏痰阻、气滞血瘀型冠心病PCI术后再狭窄的影响[J/CD].中西医结合心血管病电子杂志,2015,3(24):76-77,79.
[27]王凯丽,喻正科.护心康片干预冠心病PCI术后再狭窄32例临床观察[J].湖南中医杂志,2016,32(12):7-9.
[28]曾紫微,许滔,周竹花,等.丹蛭冰麝复方中药单体胶囊干预PCI术后再狭窄疗效研究[J].中西医结合心血管病电子杂志,2016,4(34):90-93.